How does JKTG funding further your research?
JKTG funding has been instrumental to catalyze a research project that I had great interest to pursue for many years. My project, or rather the way I asked the question, did not generate interest with the traditional government-sponsored granting mechanisms.
The project that JKTG has funded explores a fundamental question in nanomedicine for cancer therapy – how are nanoparticles transported from circulation into tumors where they can be used to kill cancer cells?
This question, we have been asking for many years and the nature of the question is at the heart of all cancer nanomedicine, which now boasts over six FDA-approved products.
Our research funded by JKTG has led us to a startling new answer that has the potential to reshape the way people think about cancer nanomedicine, and possibly revolutionize our technology approach. We would never have arrived at this answer without the JKTG funding. It’s that simple.
At Johns Hopkins’ University Kimmel Cancer Center, scientist Robert Ivkov, Ph.D., is applying his expertise in atomic and molecular structure and motion of materials to cancer. Ivkov is looking at nanotechnology – the science, engineering and manufacturing of ultra-tiny structures often called nanoparticles. Nanoparticles are one million times smaller than a human cell and Ivkov’s intent by studying nanomedicine as it relates to cancer is to see if these tiny structures can cause the immune system to fight the disease. His innovative approach causes nanoparticles injected with an added antibody to bind to breast cancer cells in tumors. The next step involves a one-of-a-kind machine built to quickly heat the tumor, which damages the cancer cells causing them to release proteins, stimulating immune cells much like a local fever which then attack the cancer cells. The hope is that this process re-engages the immune system to fight the cancer cells and win.
The Jayne Koskinas Ted Giovanis Foundation for Health and Policy (JKTG Foundation) today announced funding to develop a prototype multiscale model designed to predict therapeutic responses of tumor ecosystems – a new frontier in breast cancer research.
The word “stakeholder” really bothers me particularly in the healthcare space. I’m struck by a quote by Ken Burns.
“The thing that I’ve learned is that there is no ‘them.’ This is what everybody does: make a distinction about ‘them.’ It’s just ‘us’.”
In racing, we measure this in lap times often down to the second or tenths of a second. A recent racing article provoked me to think about the pursuit of “the last tenth” of a second in improvement which is typically the toughest and most difficult to attain.